Aerovate Therapeutics Statistics
Total Valuation
AVTE has a market cap or net worth of $68.43 million. The enterprise value is -$19.76 million.
Important Dates
The next estimated earnings date is Monday, March 24, 2025, after market close.
| Earnings Date | Mar 24, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AVTE has 28.87 million shares outstanding. The number of shares has increased by 10.95% in one year.
| Current Share Class | 28.87M |
| Shares Outstanding | 28.87M |
| Shares Change (YoY) | +10.95% |
| Shares Change (QoQ) | +0.37% |
| Owned by Insiders (%) | 0.10% |
| Owned by Institutions (%) | 45.97% |
| Float | 11.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.85 |
| P/TBV Ratio | 0.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.78, with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.78 |
| Quick Ratio | 8.60 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -82.06% and return on invested capital (ROIC) is -54.36%.
| Return on Equity (ROE) | -82.06% |
| Return on Assets (ROA) | -48.67% |
| Return on Invested Capital (ROIC) | -54.36% |
| Return on Capital Employed (ROCE) | -111.92% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.66M |
| Employee Count | 51 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AVTE has paid $56,000 in taxes.
| Income Tax | 56,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -87.39% in the last 52 weeks. The beta is 0.99, so AVTE's price volatility has been similar to the market average.
| Beta (5Y) | 0.99 |
| 52-Week Price Change | -87.39% |
| 50-Day Moving Average | 2.55 |
| 200-Day Moving Average | 4.75 |
| Relative Strength Index (RSI) | 37.24 |
| Average Volume (20 Days) | 140,808 |
Short Selling Information
The latest short interest is 4.02 million, so 13.92% of the outstanding shares have been sold short.
| Short Interest | 4.02M |
| Short Previous Month | 3.76M |
| Short % of Shares Out | 13.92% |
| Short % of Float | 33.92% |
| Short Ratio (days to cover) | 15.40 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -90.26M |
| Pretax Income | -82.13M |
| Net Income | -84.61M |
| EBITDA | -89.96M |
| EBIT | -90.26M |
| Earnings Per Share (EPS) | -$2.98 |
Full Income StatementBalance Sheet
The company has $88.73 million in cash and $540,000 in debt, giving a net cash position of $88.19 million or $3.05 per share.
| Cash & Cash Equivalents | 88.73M |
| Total Debt | 540,000 |
| Net Cash | 88.19M |
| Net Cash Per Share | $3.05 |
| Equity (Book Value) | 80.49M |
| Book Value Per Share | 2.79 |
| Working Capital | 80.29M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$74.95 million and capital expenditures -$64,000, giving a free cash flow of -$75.01 million.
| Operating Cash Flow | -74.95M |
| Capital Expenditures | -64,000 |
| Free Cash Flow | -75.01M |
| FCF Per Share | -$2.60 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |